Printer Friendly

PHYTERA, INC. AND AMERSHAM INTERNATIONAL PLC SIGN AGREEMENT TO DEVELOP ENZYMES FOR RESEARCH AND DIAGNOSTIC USE

 WORCESTER, Mass., Nov. 16 /PRNewswire/ -- Phytera, Inc. and Amersham International plc today announced that they have signed an agreement to develop and commercialize certain enzymes. The agreement is Phytera's first commercial collaboration.
 Under the agreement, the companies will establish a joint research program to identify novel enzymes derived from Phytera's plant cell culture library. Amersham will develop and market products worldwide for the research market through its Life Sciences group. The companies will share rights to products emerging from the collaboration for the clinical diagnostic market. The agreement calls for Phytera to receive from Amersham research and development support, milestone payments and royalties on product sales.
 "The collaboration with Amersham, one of the world's leading manufacturers of research reagents, represents a significant endorsement of our capabilities for generating novel compounds through plant cell culture and plant biotechnology," said Malcolm Morville, Ph.D., president and CEO of Phytera. "In addition, the agreement provides Phytera with a potential near-term revenue stream to help support our core programs to discover and develop plant-based pharmaceutical products."
 "This agreement underscores Amersham's commitment to provide life science researchers with advanced products to aid in biological discovery," said Dr. M.H. Barnes, head of business development and licensing, life sciences, for Amersham. "Phytera's innovative plant cell culture technology has significant potential to enhance our range of sensitive detection systems for the research scientist."
 Amersham International plc is a United Kingdom-based health science group and world leader in the supply of advanced products and specialized technologies for use in life sciences research, health care, and industrial quality and safety assurance.
 Phytera, Inc. is applying novel world-class capabilities in plant cell technology toward the discovery and development of plant-based pharmaceuticals to treat major human diseases. The company is based in Worcester, Mass., and maintains a plant cell biotechnology operation, Phytera Ltd., in the United Kingdom.
 -0- 11/16/93
 /CONTACT: Malcolm Morville, Ph.D., president and CEO of Phytera, 508-793-1565; Robert Gottlieb, senior vice president of Feinstein Partners, 617-577-8110, for Phytera/


CO: Phytera, Inc.; Amersham International plc ST: Massachusetts IN: MTC SU:

DJ -- NE005 -- 4883 11/16/93 08:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 16, 1993
Words:352
Previous Article:PICTURETEL ANNOUNCES COLLABORATION BETWEEN IBM PERSON TO PERSON AND PICTURETEL LIVE
Next Article:CAPITAL CITIES/ABC TO ACQUIRE 21 PERCENT STAKE IN SCANDINAVIAN BROADCASTING SYSTEM SA
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters